Abstract: Sirius Therapeutics, a China-based clinical-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. GS, Haitong, and HSBC are the joint sponsors. In our previous note, we look at the company’s core products, SRSD107, and the key product SRSD216, as well as the company’s pre-IPO investors and management team. In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.
Interested in the full report? Get in touch with our team.